506 results match your criteria Prurigo Nodularis


Safety and Effectiveness of Dupilumab in Prurigo Nodularis.

Authors:
C Romano

J Investig Allergol Clin Immunol 2020 Jun 23. Epub 2020 Jun 23.

Clinical Immunology Outpatient Clinic - Division of Internal Medicine, Department of Advanced Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18176/jiaci.0550DOI Listing

Dupilumab as a useful treatment option for prurigo nodularis in an elderly patient with atopic diathesis.

Int J Dermatol 2020 Jun 20. Epub 2020 Jun 20.

Alergoskin Alergia e Dermatologia, a UCARE Center, Santo André, São Paulo, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14994DOI Listing

Analysis of 325 Patients with Chronic Nodular Prurigo: Clinics, Burden of Disease and Course of Treatment.

Acta Derm Venereol 2020 Jun 17. Epub 2020 Jun 17.

Center for Chronic Pruritus, Department of Dermatology, University Hospital Münster, Münster, Germany.

Chronic nodular prurigo presents with multiple pruriginous nodules and severe pruritus. This study aims to explore the treatment course and regimens in patients with chronic nodular prurigo and to analyse predictive factors contributing to therapeutic success. A total of 325 patients with chronic nodular prurigo (m 37. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3571DOI Listing

Delusional Infestation Can Be a Complication of Prurigo Nodularis with Underlying Neuropathies.

Acta Derm Venereol 2020 Jun 18. Epub 2020 Jun 18.

Department of Dermatology, University Hospital of Brest, 47 rue Louis Pasteur, FR-29200 Brest, France. E-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3579DOI Listing

Prevalence of Prurigo Nodularis in the United States.

J Allergy Clin Immunol Pract 2020 Jun 9. Epub 2020 Jun 9.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2020.05.051DOI Listing

New and Emerging Treatments for Inflammatory Itch.

Ann Allergy Asthma Immunol 2020 Jun 1. Epub 2020 Jun 1.

Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, 63110; Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, 63110; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, 63110; Center for the Study of Itch and Sensory Disorders, Washington University School of Medicine, St. Louis, MO, 63110. Electronic address:

Objective: Chronic pruritus, or itch lasting >6 weeks, is a common symptom and has a profoundly negative impact on quality of life. While many primary dermatologic disorders such as atopic dermatitis and chronic urticaria are characterized by pruritus, numerous other allergic, hepatobiliary, lymphoproliferative, neurologic, and renal disorders are associated with chronic pruritus. Itch involves complex interactions orchestrated by a variety of factors released from and acting on the skin, immune system, and the sensory nervous system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anai.2020.05.028DOI Listing

Trends in the Demographics and Treatment of Prurigo Nodularis in the United States.

J Cutan Med Surg 2020 Jun 4:1203475420931763. Epub 2020 Jun 4.

12303 Department of Dermatology, College of Medicine, Cincinnati, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420931763DOI Listing

The impact of prurigo nodularis on sleep disturbance and related impact: a systematic review.

J Eur Acad Dermatol Venereol 2020 Jun 3. Epub 2020 Jun 3.

The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.16696DOI Listing

[Clinical characteristics of patients with prurigo nodularis: A descriptive study].

Ann Dermatol Venereol 2020 May 28. Epub 2020 May 28.

Service de dermatologie, CHU de Brest, 2, avenue Foch, 29609 Brest cedex, France; Université de Brest, LIEN, 29200 Brest, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annder.2020.04.010DOI Listing

Dupilumab for treatment-refractory prurigo nodularis.

J Dtsch Dermatol Ges 2020 Jun 29;18(6):618-624. Epub 2020 May 29.

Center for Research on Inflammation of the Skin, University of Lübeck, Lübeck, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.14107DOI Listing

Prurigo Nodularis: Pathogenesis and Management.

J Am Acad Dermatol 2020 May 24. Epub 2020 May 24.

Johns Hopkins University School of Medicine, Department of Dermatology; Johns Hopkins University Bloomberg School of Public Health. Electronic address:

Prurigo nodularis (PN) is a chronic skin condition characterized by severely pruritic nodules that cause a profound negative impact on quality of life. In the second article of this 2-part continuing medical education series, we focus on reviewing pathogenesis of prurigo nodularis and explore management algorithms for this condition. Additionally, we will discuss some emerging and novel therapies for treating PN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.04.182DOI Listing

Prurigo Nodularis: Epidemiology and Clinical Features.

J Am Acad Dermatol 2020 May 23. Epub 2020 May 23.

Johns Hopkins University School of Medicine, Department of Dermatology; Johns Hopkins University Bloomberg School of Public Health. Electronic address:

Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules that favor the extensor surfaces of the extremities and the trunk. In addition to its significant impact on quality of life, many patients with PN are recalcitrant to therapy as there are currently no FDA approved therapies. In the first article of this 2-part continuing medical education series, we describe the broader epidemiology, patient demographics, physical exam findings, and symptoms to aid in the timely recognition and diagnosis of PN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.04.183DOI Listing

[THREE CASES OF ATOPIC DERMATITIS CHILDREN WITH INTRACTABLE PRURIGO NODULARIS].

Arerugi 2020 ;69(3):213-217

Department of Pediatrics, National Hospital Organization Fukuoka National Hospital.

Background: Prurigo nodularis is a chronic disease characterized by a hard dome-like or wart-like nodule which is solitary and does not fuse. Prurigo nodularis presents as one of the symptoms of atopic Dermatitis (AD).

Cases: We present three cases of AD children with intractable prurigo nodularis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15036/arerugi.69.213DOI Listing
January 2020

Prevalence of Prurigo Nodularis in Poland.

Acta Derm Venereol 2020 May 28;100(10):adv00155. Epub 2020 May 28.

Department of Dermatology, University of Rzeszow, Szopena street 2, PL-35-055 Rzeszów, Poland.

Prurigo nodularis is a chronic skin condition that presents significant challenges for treatment and quality of life, with little known about disease prevalence. This study assessed the prevalence of prurigo nodularis in Poland using publicly maintained database case records and diagnostic codes for prurigo nodularis (L28.1) and other prurigo (L28. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3518DOI Listing

Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature.

Int J Dermatol 2020 Jun 20;59(6):716-721. Epub 2020 Apr 20.

Dermatologic Clinic, Sapienza University of Rome, Rome, Italy.

Background: Atopic dermatitis (AD) is a chronic relapsing eczematous dermatitis typically affecting young patients in a percentage from 15 to 20%; although it typically affects young people and adults, recent papers highlighted the emerging of the disease in the elderly population.

Methods: The aim of the study was to identify the clinical criteria and allergic sensitization that may be able to support physicians and dermatologists in making a correct diagnosis of AD in the elderly. The second aim of this study was to investigate the incidence, the main features, the gender prevalence, the immunological profile, and comorbidities characterizing patients older than 65 years affected by AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14891DOI Listing

Nevus sebaceus with syringocystadenoma papilliferum, prurigo nodularis, apocrine cystadenoma, basaloid follicular proliferation, and sebaceoma: case report and review of nevus sebaceus-associated conditions.

Dermatol Online J 2020 Feb 15;26(2). Epub 2020 Feb 15.

School of Medicine, University of California San Diego, La Jolla, CA.

Nevus sebaceus is a benign skin hamartoma of congenital onset that grows during puberty, and in adulthood can develop secondary benign and malignant neoplasms. The most common benign neoplasms occurring in nevus sebaceus are believed to be syringocystadenoma papilliferum, trichilemmoma, and trichoblastoma. A patient with nevus sebaceus developed not only syringocystadenoma papilliferum but also prurigo nodularis within her hamartomatous lesion; multiple biopsies were necessary to establish the diagnoses. Read More

View Article

Download full-text PDF

Source
February 2020

Treatment and Burden of Disease in a Cohort of Patients with Prurigo Nodularis: A Survey-based Study.

Acta Derm Venereol 2020 Apr 21;100(8):adv00119. Epub 2020 Apr 21.

Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark.

Prurigo nodularis is a pruritic dermatosis with poor treatment options. To describe treatment patterns, comorbidities, pruritus, and quality of life a survey was administered to 92 patients with prurigo nodularis. A total of 52 patients completed the survey. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3471DOI Listing

Efficacy of Apremilast in Patients with Prurigo Nodularis: A Proof-of-concept Study.

Acta Derm Venereol 2020 Apr 21;100(8):adv00118. Epub 2020 Apr 21.

Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3461DOI Listing

Prurigo nodularis: New treatments on the horizon.

Authors:
Gil Yosipovitch

J Am Acad Dermatol 2020 Apr;82(4):1035-1036

Dr Phillip Frost Department of Dermatology and Cutaneous Surgery and Itch Center Miller School of Medicine, University of Miami, Miami, Florida. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.02.061DOI Listing

Association of prurigo nodularis and lichen simplex chronicus with hospitalization for mental health disorders in US adults.

Arch Dermatol Res 2020 Feb 20. Epub 2020 Feb 20.

Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Suite 2B-425, 2150 Pennsylvania Avenue NW, Washington, DC, 20037, USA.

Prurigo nodularis (PN) and lichen simplex chronicus (LSC) are debilitating chronic pruritic diseases that can lead to and be exacerbated by psychosocial distress. However, little is known about the mental health (MH) comorbidities of PN/LSC. We sought to evaluate the likelihood and cost-burden of MH comorbidities and emergencies associated with PN/LSC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00403-020-02046-5DOI Listing
February 2020
2.270 Impact Factor

Breaking the Itch-Scratch Cycle in Prurigo Nodularis.

Authors:
Shawn G Kwatra

N Engl J Med 2020 02;382(8):757-758

From the Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1916733DOI Listing
February 2020

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.

N Engl J Med 2020 02;382(8):706-716

From the Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster (S.S.), the Department of Dermatology and Allergy, Christine Kühne Center for Allergy Research and Education, University Hospital, Bonn (T.B.), and the Department of Dermatology and Allergy, Ludwig Maximilian University of Munich, Munich (A.W.) - all in Germany; the Itch Center, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Hospital, Miami (G.Y.); the Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria (F.J.L.); the Department of Dermatology, University Hospital of Nice, Nice (J.-P.L.), the Department of Dermatology, University of Toulouse, Toulouse (C. Paul), and the Department of Dermatology, University Hospital of Brest, Brest (L.M.) - all in France; the Department of Dermatology, Medical University of Lodz, Lodz (J.N.), and the Department of Dermatology, University of Rzeszow, Rzeszow (A.R.) - both in Poland; Galderma, Fort Worth, TX (F.A.); and Galderma, Lausanne, Switzerland (C. Piketty).

Background: Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis.

Methods: We conducted a 12-week, randomized, double-blind, phase 2 trial of nemolizumab (at a dose of 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1908316DOI Listing
February 2020

Response: Management challenges in prurigo nodularis.

J Dermatolog Treat 2020 Feb 21:1-2. Epub 2020 Feb 21.

Department of Medicine, Division of Dermatology, University of Arizona, Tucson, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2020.1729953DOI Listing
February 2020

Dupilumab for bullous pemphigoid with intractable pruritus.

Dermatol Online J 2019 Nov 15;25(11). Epub 2019 Nov 15.

Department of Dermatology, University of California San Diego, San Diego, CA.

Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. Treatment regimens typically include topical and systemic immunosuppressive medications. Although effective, systemic corticosteroids are sometimes poorly tolerated in the elderly patient, contributing to the overall morbidity and mortality of BP. Read More

View Article

Download full-text PDF

Source
November 2019

Healthcare resource utilization and payer cost analysis of patients with prurigo nodularis.

Br J Dermatol 2020 Feb 4. Epub 2020 Feb 4.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.18925DOI Listing
February 2020

Sleep quality among adult patients with chronic dermatoses.

Postepy Dermatol Alergol 2019 Dec 9;36(6):659-666. Epub 2019 Apr 9.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.

Chronic dermatoses, including atopic dermatitis, psoriasis, prurigo nodularis, chronic spontaneous urticaria and hidradenitis suppurativa, as well as accompanying subjective symptoms (itch and pain), have a great impact on patients' well-being. Skin plays an important role in the physiological sleep process. This review attempts to analyze the association between chronic dermatoses in adults and sleep quality in recent studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/ada.2019.84007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986286PMC
December 2019

Cannabinoids for the treatment of chronic pruritus: A review.

J Am Acad Dermatol 2020 May 25;82(5):1205-1212. Epub 2020 Jan 25.

Division of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio. Electronic address:

Medical marijuana is becoming widely available to patients in the United States, and with recreational marijuana now legalized in many states, patient interest is on the rise. The endocannabinoid system plays an important role in skin homeostasis in addition to broader effects on neurogenic responses such as pruritus and nociception, inflammation, and immune reactions. Numerous studies of in vitro and animal models have provided insight into the possible mechanisms of cannabinoid modulation on pruritus, with the most evidence behind neuronal modulation of peripheral itch fibers and centrally acting cannabinoid receptors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.01.036DOI Listing

Association between Prurigo Nodularis and Etiologies of Peripheral Neuropathy: Suggesting a Role for Neural Dysregulation in Pathogenesis.

Medicines (Basel) 2020 Jan 8;7(1). Epub 2020 Jan 8.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

: Prurigo nodularis (PN) is an intensely pruritic skin condition of considerable morbidity. However, the pathogenesis of PN and its association with underlying neuropathy is unclear. : We sought to investigate the association between PN and etiologies of peripheral neuropathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/medicines7010004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167799PMC
January 2020

Dupilumab for prurigo nodularis: Case series and review of the literature.

Dermatol Ther 2020 Mar 16;33(2):e13222. Epub 2020 Jan 16.

Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.

Dupilumab is a recombinant complete human monoclonal antibody modulating the signaling of interleukin-4 and interleukin-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. Here, we present three cases of prurigo nodularis treated off-label with dupilumab, and a review of the existing literature. All patients in this study had longstanding severe disease and had tried multiple treatment modalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13222DOI Listing

Chronic prurigo: A retrospective study of 168 cases.

J Dermatol 2020 Mar 6;47(3):283-289. Epub 2020 Jan 6.

Department of Dermatology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.

Chronic prurigo is classified into two clinical subtypes: prurigo nodularis (PN) and prurigo chronica multiformis (PCM) in Japan. In this study, we retrospectively investigated the clinical features of 168 patients with chronic prurigo (103 with PN and 65 with PCM) diagnosed at the Tokyo Medical and Dental University, and compared age, sex, prevalence of comorbidities, blood test results, histology and treatment efficacy in both groups. We found that patients with PCM were significantly older than those with PN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.15212DOI Listing

Emerging novel therapeutic agents for the treatment of patients with prurigo nodularis.

J Dermatolog Treat 2020 Jan 3:1-4. Epub 2020 Jan 3.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1707469DOI Listing
January 2020

Efficacy of dupilumab in prurigo nodularis in elderly patient.

Dermatol Ther 2020 01 28;33(1):e13201. Epub 2019 Dec 28.

Medical Sciences Department, Dermatologic Clinic, University of Turin, Turin, Italy.

Prurigo nodularis (PN) is a chronic disorder, affecting adults, with multiple nodules, typically on the limbs. The treatment is challenging, especially in elderly patients. An 85-year-old woman had developed in the last 3 years itch with nodular lesions and erythematous scaly patches and excoriations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13201DOI Listing
January 2020
1.478 Impact Factor

Implementation of an Ultraviolet Phototherapy Service at a National Referral Hospital in Western Kenya: Reflections on Challenges and Lessons Learned.

Dermatol Ther (Heidelb) 2020 Feb 16;10(1):107-117. Epub 2019 Nov 16.

Department of Dermatology, University of California, San Francisco, CA, USA.

Introduction: In order to manage skin conditions at a national referral hospital level in Kenya, specialized dermatology services, such as dermatologic surgery, dermatopathology, phototherapy, and sub-specialty care, should be offered, as is typically available in referral hospitals around the world. A Kenyan patient with prurigo nodularis, whose severe itch remitted after phototherapy treatment at the University of California, San Francisco (UCSF), inspired the development of a phototherapy service at Academic Model Providing Access to Healthcare (AMPATH), a partnership in Western Kenya between Moi Teaching and Referral Hospital, Moi University College of Health Sciences, and a consortium of North American academic medical centers.

Methods: Initial project funds were raised through a crowdfunding campaign and fundraising events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13555-019-00342-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994574PMC
February 2020
2 Reads

Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.

J Dermatolog Treat 2019 Nov 12:1-10. Epub 2019 Nov 12.

Department of Medicine, Division of Dermatology, University of Arizona, Tucson, AZ, USA.

While dupilumab has emerged as an effective treatment for moderate-to-severe atopic dermatitis (AD) since its approval in 2017, interleukin-4 and 13 blockade has also demonstrated efficacy in off-label chronic dermatologic conditions. To identify chronic dermatologic conditions in which dupilumab has demonstrated efficacy. Thirty-three reports of dupilumab use in non-AD dermatologic conditions were identified through systematic literature review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1689227DOI Listing
November 2019
7 Reads

Paraneoplastic eczematous eruption associated with Hodgkin's lymphoma.

Proc (Bayl Univ Med Cent) 2019 Oct 5;32(4):587-588. Epub 2019 Aug 5.

Department of Dermatology, Texas Tech University Health Sciences CenterLubbockTexas.

Hodgkin's disease (HD) is a common malignant lymphoma that classically presents with painless lymphadenopathy, weight loss, nocturnal sweats, fever, and generalized pruritus. Unlike other lymphoproliferative disorders, cutaneous involvement is uncommon with HD. Diffuse hyperpigmentation, prurigo nodularis, acquired ichthyosis, erythema nodosum, mycosis fungoides, herpes zoster, and vasculitis have all been described as nonspecific or paraneoplastic manifestations of HD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08998280.2019.1644148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794004PMC
October 2019
1 Read

Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis

J Drugs Dermatol 2019 Oct;18(10)

Dupilumab inhibits the interleukin-4 receptor subunit α and is FDA approved for treatment of moderate-to-severe atopic dermatitis. It is a relatively new drug, and whether it is efficacious for other diseases in dermatology is an area of increasing interest. We searched the literature and ClinicalTrials. Read More

View Article

Download full-text PDF

Source
October 2019
4 Reads

Racial and Gender Differences in the Presentation of Pruritus.

Medicines (Basel) 2019 Sep 27;6(4). Epub 2019 Sep 27.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Pruritus is a common disease symptom with a variety of etiologies known to reduce patient quality of life. We aimed to characterize the racial and gender differences in the presentation of pruritus for itch-related patient visits both within a single institution and nationally. Cross sectional study of patients ≥ 18 years old seen at Johns Hopkins Health System between 1/1/12 and 1/1/18. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/medicines6040098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963580PMC
September 2019
1 Read

Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis.

Eur J Pharmacol 2019 Dec 27;864:172702. Epub 2019 Sep 27.

Center for Substance Abuse Research, Lewis Katz Medical School at Temple University, Philadelphia, PA, USA; Department of Pharmacology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.

Chronic itch is one of the disturbing symptoms of inflammatory skin diseases. Kappa opioid receptor agonists are effective in suppressing scratching in mice against different pruritogens. Nalbuphine, a nonscheduled kappa opioid receptor agonist and mu opioid receptor antagonist, has been in clinical use for post-operative pain management since the 1980s and recently has been in clinical trials for chronic itch of prurigo nodularis (https://www. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2019.172702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913640PMC
December 2019
4 Reads

Eosinophilic dermatoses.

J Dtsch Dermatol Ges 2019 10 27;17(10):1039-1051. Epub 2019 Sep 27.

Department of Dermatology, University Hospital, Jena, Germany.

Eosinophilic dermatoses are a heterogeneous group of diseases, characterized by an eosinophil-rich infiltrate and/or degranulation of eosinophils. Blood eosinophilia may be an associated feature. Typical, albeit not specific histological findings include 'flame figures', which are caused by the accumulation of cationic proteins released by eosinophils and subsequent collagen denaturation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.13943DOI Listing
October 2019
2 Reads

Diagnostic Workup and Evaluation of Patients with Prurigo Nodularis.

Medicines (Basel) 2019 Sep 26;6(4). Epub 2019 Sep 26.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized oftentimes by symmetrically distributed, severely pruritic nodules. Currently, the pathophysiology of PN remains to be fully elucidated, but emerging evidence suggests that neuroimmune alterations play principal roles in the pathogenesis of PN. There are several associated etiologic factors thought to be associated with PN, including dermatoses, systemic, infectious, psychiatric, and neurologic conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/medicines6040097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963711PMC
September 2019
2 Reads

Role of Dermoscopy in the Diagnosis of Hypertrophic Lichen Planus and Prurigo Nodularis.

Indian J Dermatol 2019 Sep-Oct;64(5):341-345

Department of Skin and VD, Mysore Medical College and Research Institute, Mysore, Karnataka, India.

Background: A dermoscope is an office tool used in the diagnosis of various disorders. At present, studies on hypertrophic lichen planus (HLP) and prurigo nodularis (PN) are limited.

Aims And Objectives: The aim of this study was to compare the dermoscopic features of HLP and PN and to determine the role of dermoscopy in the differential diagnosis of both the conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijd.IJD_123_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749763PMC
September 2019
2 Reads

Dupilumab Treatment for Prurigo Nodularis and Pruritis

J Drugs Dermatol 2019 Sep;18(9):940-942

Prurigo nodularis (PN) is a disease in which chronic scratching and picking of the skin due to intense pruritis results in papulonodules, notably in areas that are accessible to the patient. The pathophysiology is hypothesized to be mediated by a Th2 helper cell response, similar to that seen in atopic dermatitis, therefore, treatment of PN with dupilumab would be expected to elicit a therapeutic response. We demonstrated that treatment of PN with dupilumab significantly decreased pruritis and the size and number of new lesions after 2 months of treatment. Read More

View Article

Download full-text PDF

Source
September 2019
2 Reads

Analysis of real-world treatment patterns in patients with prurigo nodularis.

J Am Acad Dermatol 2020 Jan 12;82(1):34-36. Epub 2019 Sep 12.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.09.007DOI Listing
January 2020
3 Reads

Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis.

Dermatitis 2020 Jan 3. Epub 2020 Jan 3.

Department of Health Sciences, University Magna Graecia of Catanzaro, Italy.

Background: Generalized prurigo nodularis (GPN) is a debilitating, inflammatory skin disease characterized by chronic pruritus, signs of prolonged scratching, and multiple pruriginous papules and nodules. Recent studies identified several forms of GPN as a clinical phenotype of adult atopic dermatitis (AD).

Objective: The aim of the study was to evaluate the effectiveness of dupilumab (D) in adults affected by persistent AD showing a clinical feature of GPN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DER.0000000000000517DOI Listing
January 2020
2 Reads

The Neuromodulatory Effect of Antipruritic Treatment of Chronic Prurigo.

Dermatol Ther (Heidelb) 2019 Dec 11;9(4):613-622. Epub 2019 Sep 11.

Department of Dermatology and Center for Chronic Pruritus, University Hospital of Münster, Münster, Germany.

Chronic prurigo is an extremely severe pruritic skin disease which presents with multiple, hyperkeratotic and erosive papules, nodules and/or plaques. Patients with this high-burden disease require effective therapies, but effective treatments with regulatory agency approval are currently lacking. Deeper understanding of the pathophysiology suggests that hypersensitive nerves play an important role in the development of chronic prurigo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13555-019-00321-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828989PMC
December 2019
1 Read

Racial differences in dermatologic conditions associated with HIV: A cross-sectional study of 4679 patients in an urban tertiary care center.

J Am Acad Dermatol 2020 May 6;82(5):1117-1123. Epub 2019 Sep 6.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Electronic address:

Background: Because of reduced mortality, patients with HIV are living longer and presenting with chronic diseases. Little is known about racial differences in dermatologic conditions associated with HIV infection.

Objective: This study examines associated dermatologic conditions in a large population of patients with HIV at a tertiary care center with a diverse patient population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.08.072DOI Listing
May 2020
2 Reads

IL-17A Induces Endothelin-1 Expression through p38 Pathway in Prurigo Nodularis.

J Invest Dermatol 2020 Mar 30;140(3):702-706.e2. Epub 2019 Aug 30.

Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2019.08.438DOI Listing
March 2020
3 Reads

Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1/2 activation.

J Eur Acad Dermatol Venereol 2019 Dec 12;33(12):2371-2379. Epub 2019 Sep 12.

Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany.

Background: Aprepitant is a neurokinin 1 receptor (NK1R) antagonist used for its antipruritic properties in dermatoses and systemic diseases. The mode of action is still unclear. A peripheral effect is assumed as aprepitant shows efficacy in inflammatory skin diseases including prurigo nodularis (PN). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15905DOI Listing
December 2019
3 Reads